Overview

Aspect Biosystems is a Canadian biotechnology company developing bioprinted tissue therapeutics, a new class of regenerative medicines intended to deliver functional cures for serious diseases. The company integrates microfluidic 3D bioprinting, therapeutic cell development, and biomaterials engineering to create implantable tissues, supported by teams spanning R&D, Process Development/CMC, Technical Operations, Quality Control/Analytical Development, Engineering, and Translational Sciences. Work at Aspect ranges from scaling cell production and formulating GMP-ready biomaterials to validating assays (viability, potency, identity, purity), managing multimodal scientific data, and characterizing host responses in preclinical models. The organization emphasizes reproducibility, data integrity, and regulatory compliance (GxP; FDA/EMA guidance) while building FAIR data practices and robust documentation. Aspect’s mission is to transform how disease is treated through bioprinted tissues, and its culture highlights curiosity, collaboration, and accountability in a fast-paced, cross-functional environment. The company states a commitment to diversity, equity, and inclusion and to creating a merit-based workplace.